DEFA14A: Zymeworks Schedules 2025 Annual Stockholder Meeting
Proxy Statement / Annual Meeting Notice
Zymeworks Inc. announced its Annual Meeting of Stockholders for December 30, 2025, to address director elections, executive compensation, and auditor ratification.
Summary
- The Annual Stockholder Meeting is scheduled for December 30, 2025, at 9:00 a.m. Pacific Time, to be held virtually via the Internet at meetnow.global/MZKC5MK.
- Shareholders will vote on the election of three director nominees: Carlos Campoy, Alessandra Cesano, and Robert E. Landry.
- An advisory vote on the compensation of named executive officers is included on the agenda.
- The ratification of KPMG LLP, chartered professional accountants, as auditors for the year ending December 31, 2025, will also be voted upon.
- The Board of Directors recommends a vote FOR all director nominees and FOR Proposals 2 (executive compensation) and 3 (auditor ratification).
- Proxy materials, including the Notice, Proxy Statement, and Annual Report on Form 10-K, are available online for review.
- Shareholders can vote online or request paper copies of the proxy materials; requests for paper copies must be made by December 20, 2025, for timely delivery.
Sentiment
Score: 5
Explanation: The filing is a routine proxy statement for an annual meeting, providing standard corporate governance information without any specific positive or negative operational or financial news.
Positives
- The filing represents a routine and transparent corporate governance process, ensuring shareholder participation in key company decisions.
Negatives
- The filing is a standard administrative proxy statement and does not contain specific negative operational or financial news.
Future Outlook
The filing outlines future corporate governance events, specifically the Annual Meeting of Stockholders and the proposals to be voted upon, but does not provide forward-looking statements regarding business operations or financial performance.
Management Comments
- The Board of Directors recommends a vote FOR all the director nominees listed and FOR Proposals 2 (advisory vote on executive compensation) and 3 (ratification of auditors).
Industry Context
This announcement is a standard annual meeting proxy statement, a routine corporate governance practice for all publicly traded companies, reflecting compliance with regulatory requirements in the biotechnology and pharmaceutical industry.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director Nominee | N/A (up for election/re-election) | Carlos Campoy | Post-Annual Meeting (if elected) | Proposed for election to the Board of Directors |
| Director Nominee | N/A (up for election/re-election) | Alessandra Cesano | Post-Annual Meeting (if elected) | Proposed for election to the Board of Directors |
| Director Nominee | N/A (up for election/re-election) | Robert E. Landry | Post-Annual Meeting (if elected) | Proposed for election to the Board of Directors |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election Proposal | Shareholders will vote on the election of three director nominees: Carlos Campoy, Alessandra Cesano, and Robert E. Landry. | Post-Annual Meeting (if elected) | Ensures board continuity or refreshment, influencing strategic oversight and governance. |
| Executive Compensation Advisory Vote | An advisory vote on the compensation of named executive officers will be held. | N/A (advisory) | Provides shareholders with a voice on executive pay practices, influencing future compensation decisions. |
| Auditor Ratification | Ratification of KPMG LLP as the company's independent auditors for the fiscal year ending December 31, 2025. | Post-Annual Meeting (if ratified) | Confirms the appointment of an independent auditor, crucial for financial transparency and regulatory compliance. |
Stakeholder Impact
- Shareholders: Provided with the opportunity to exercise their voting rights on critical corporate governance matters, including board composition, executive compensation, and auditor selection.
- Management and Board of Directors: Subject to shareholder approval for director elections and receive advisory feedback on executive compensation, influencing accountability and future governance strategies.
- Auditors (KPMG LLP): Their appointment for the upcoming fiscal year is subject to shareholder ratification, affirming their role in ensuring financial integrity.
Next Steps
- Shareholders are encouraged to access and review the complete proxy materials online.
- Shareholders are to cast their votes on the election of directors, the advisory vote on executive compensation, and the ratification of auditors.
- The Annual Meeting of Stockholders will convene on December 30, 2025.
Key Dates
| Date | Description |
|---|---|
| 2025-12-20 | Deadline to request a paper copy of proxy materials for timely delivery. |
| 2025-12-24 | Deadline for registered shareholders to submit voting instruction cards by 2:00 pm Eastern Time (via mail, internet, or telephone). |
| 2025-12-25 | Deadline for shares held via Shareworks to vote by 11:59 p.m. ET. |
| 2025-12-30 | Annual Meeting of Stockholders at 9:00 a.m. Pacific Time. |
| 2025-12-31 | Year-end for which KPMG LLP is appointed as auditors. |
Keywords
Zymeworks, Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Executive Compensation, Auditor Ratification, SEC Filing, DEFA14A
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.